Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells

Hypertension

Volumn 56, Issue 3, 2010, Pages 384-390

  Zhu, Liping ^a   Carretero, Oscar A ^a   Liao, Tang Dong ^a   Harding, Pamela ^a   Li, Hongwei ^b   Sumners, Colin ^b   Yang, Xiao Ping ^a  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

angiotensin II type 2 receptor; bradykinin; coronary artery endothelial cells; plasma kallikrein kinin system; prolylcarboxypeptidase

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADENOVIRUS VECTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PROLINE CARBOXYPEPTIDASE; SMALL INTERFERING RNA; VALSARTAN;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE OVEREXPRESSION; KALLIKREIN KININ SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRADYKININ; CARBOXYPEPTIDASES; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; GENE TRANSFER TECHNIQUES; IMMUNOENZYME TECHNIQUES; KALLIKREIN-KININ SYSTEM; KALLIKREINS; MALE; MICE; RECEPTOR, ANGIOTENSIN, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 77955982778     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.155051     Document Type: Article

References (36)

1. Schulman IH, Raij L. The angiotensin II type 2 receptor: what is its clinical significance? Curr Hypertens Rep. 2008;10:188-193.
2. 2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323-336.
3. Hutchinson HG, Hein L, Fujinaga M, Pratt RE. Modulation of vascular development and injury by angiotensin II. Cardiovasc Res. 1999;41: 689-700.
4. Gallinat S, Busche S, Raizada MK, Sumners C. The angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol Endocrinol Metab. 2000;278:E357-E374.
5. Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. J Renin Angiotensin Aldosterone Syst. 2005;6: 43-48.
6. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Car-retero OA. Effects of angiotensin-converting enzyme inhibitors and an-giotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99: 1926-1935.
7. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31:349-355.
8. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A
9. Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
10. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K, Matsubara H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension. 2003;41:99-107.
11. Bove CM, Yang Z, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Matsubara H, Carey RM, Kramer CM. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarct remodeling. Hypertension. 2004;43:680-685.
12. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Laragh JH, Brenner BM, eds. Hypertension: Physiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:983-999.
13. Yang HYT, Erdös EG, Chiang TS. New enzymatic route for the inacti-vation of angiotensin. Nature. 1968;218:1224-1226.
14. Kumamoto K, Stewart TA, Johnson AR, Erdos EG. Prolylcarboxypep-tidase (angiotensinase C) in human lung and cultured cells. J Clin Invest. 1981;67:210-215.
15. Moreira CR, Schmaier AH, Mahdi F, da Motta G, Nader HB, Shariat-Madar Z. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett. 2002;523:167-170. (Pubitemid 34786080)
16. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdös EG. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem. 1978;253:5927-5931.
17. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002;277:17962-17969. (Pubitemid 34967607)
18. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcar- boxypeptidase activates plasma prekallikrein. Blood. 2004;103: 4554-4561.
19. Ngo ML, Mahdi F, Kolte D, Shariat-Madar Z. Upregulation of prolyl-carboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endotheli-um promotes inflammation. J Inflamm (Lond). 2009;6:3.
20. Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood. 1998;91:516-528.
21. Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol. 2005;289: H2697-H2703.
22. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Røjkjaer R, Schmaier AH. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol. 2001;280:H1821-H1829.
23. Qin XP, Zeng SY, Tian HH, Deng SX, Ren JF, Zheng YB, Li D, Li YJ, Liao DF, Chen SY. Involvement of prolylcarboxypeptidase in the effect of rutaecarpine on the regression of mesenteric artery hypertrophy in renovascular hypertensive rats. Clin Exp Pharmacol Physiol. 2009;36: 319-324.
24. 1 antagonists in mice. Hypertension. 2002;40:244-250.
25. 2 kinin receptor gene knockout mice. Circ Res. 2001;88:1072-1079.
26. Teng B, Ansari HR, Oldenburg PJ, Schnermann J, Mustafa SJ. Isolation and characterization of coronary endothelial and smooth muscle cells from A1 adenosine receptor-knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:H1713-H1720.
27. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol. 1984;99:2034-2040.
28. Dame MK, Yu X, Garrido R, Bobrowski W, McDuffie JE, Murphy HS, Albassam M, Varani J. A stepwise method for the isolation of endothelial cells and smooth muscle cells from individual canine coronary arteries. In Vitro Cell Dev Biol Anim. 2003;39:402-406.
29. Li H, Gao Y, Grobe JL, Raizada MK, Katovich MJ, Sumners C. Poten-tiation of the antihypertensive action of losartan by peripheral overex-pression of the ANG II type 2 receptor. Am J Physiol Heart Circ Physiol. 2007;292:H727-H735.
30. Wang F, He Q, Sun Y, Dai X, Yang XP. Female adult mouse cardio-myocytes are protected against oxidative stress. Hypertension. 2010;55: 1172-1178.
31. Motta G, Shariat-Madar Z, Mahdi F, Sampaio CA, Schmaier AH. Assembly of high molecular weight kininogen and activation of prekal-likrein on cell matrix. Thromb Haemost. 2001;86:840-847.
32. Jin X-Q, Fukuda N, Su J-Z, Lai Y-M, Suzuki R, Tahira Y, Takagi H, Ikeda Y, Kanmatsuse K, Miyazaki H. Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertension. 2002;39:1021-1027.
33. Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, Katovich MJ, Sumners C. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 2009;8:3255-3265.
34. Miura S, Karnik SS, Saku K. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem. 2005;280: 18237-18244.
35. Metcalfe BL, Huentelman MJ, Parilak LD, Taylor DG, Katovich MJ, Knot HJ, Sumners C, Raizada MK. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer. Hypertension. 2004;43: 1233-1238.
36. Coffman LG, Brown JC, Johnson DA, Parthasarathy N, D'Agostino RB Jr, Lively MO, Hua X, Tilley SL, Muller-Esterl W, Willingham MC, Torti FM, Torti SV. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol. 2008;294:L505-L515.